Doxycycline in Type II Diabetes

Phase 2RecruitingNCT06329882

Mostafa Bahaa60 enrolled

Overview

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus, Type 2

Interventions

Sitagliptin 100mgDRUG

Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes

DoxycyclinDRUG

Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth.

Eligibility

Sex: ALLMin age: 40 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5 Exclusion Criteria: * Patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation

Locations (1)

Tanta Unuversity

Tanta, Egypt

RECRUITING

Outcomes

Primary Outcomes

Change in glycemic profile

measurement of fasting blood glucose (FBG)

Time frame: 3 months

Change in glycemic profile

measurement of glycated hemoglobin

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.